Key result
Uninterrupted rivaroxaban during dental implant surgery is linked to similar bleeding rates as healthy controls.
Why the study?
The safety of performing dental implant surgery without interrupting or modifying oral rivaroxaban anticoagulant therapy was evaluated due to concerns about bleeding complications.
Does uninterrupted rivaroxaban therapy increase bleeding complications during dental implant surgery compared to healthy controls?
Cohort (n=57)
Does uninterrupted rivaroxaban therapy increase bleeding complications during dental implant surgery compared to healthy controls?
Relative Risk: 0.919 (95% CI 0.078–10.844)
Absolute Event Rate: 5.6% vs 5.1%
p-value: p=0.688
Dental implant surgery can be safely performed in patients on uninterrupted rivaroxaban using local hemostatic measures without an increased risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Comparable bleeding supports uninterrupted rivaroxaban with local hemostasis in implants; leaves open confirmation in larger prospective trials.
Moreno et al. (2015) conducted a cohort in Dental implant surgery (n=57). Rivaroxaban continuation vs. Healthy subjects was evaluated on Bleeding complications (RR 0.919, 95% CI 0.078-10.844, p=0.688). Uninterrupted rivaroxaban therapy during dental implant surgery was associated with similar bleeding rates compared to healthy controls (5.6% vs 5.1%; RR 0.919; 95% CI 0.078-10.844; P=0.688).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: